MAGEA3 and head and neck squamous cell carcinoma: The induction of MAGEA3 and HPV-specific T cell responses detected in TILs and PBMCs demonstrated the immunogenicity of this peptide vaccine [67] with acceptable toxicity but no clinical effect in advanced HNSCC.